Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences.
暂无分享,去创建一个
D. Wortham | P K Honig | D. Conner | L. Cantilena | D C Wortham | K Zamani | D P Conner | J C Mullin | L R Cantilena | P. Honig | K. Zamani | J. Mullin | Peter K. Honig | Dale C. Wortham | Dale P. Conner
[1] G. Danan,et al. Self-induction by erythromycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P-450. , 1981, The Journal of pharmacology and experimental therapeutics.
[2] R. Hook,et al. Pharmacokinetics and biotransformation studies of terfenadine in man. , 1982, Arzneimittel-Forschung.
[3] D. Feldman,et al. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. , 1983, The Journal of clinical investigation.
[4] Benjamin S. Duran,et al. Statistical Methods for Engineers and Scientists , 1985 .
[5] S. Nattel,et al. Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism. , 1990, The American journal of medicine.
[6] C. L. Ferguson,et al. Torsades de pointes occurring in association with terfenadine use. , 1990, JAMA.
[7] Jan Pool,et al. QTc Prolongation Measured by Standard 12‐Lead Electrocardiography Is an Independent Risk Factor for Sudden Death Due to Cardiac Arrest , 1991, Circulation.
[8] J. Coutant,et al. Determination of terfenadine and terfenadine acid metabolite in plasma using solid-phase extraction and high-performance liquid chromatography with fluorescence detection. , 1991, Journal of chromatography.
[9] B McNutt,et al. Torsades de pointes occurring in association with terfenadine use. , 1991, JAMA.
[10] R. Woosley,et al. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin , 1992, Clinical pharmacology and therapeutics.
[11] J. García-Sancho,et al. High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors. , 1992, The Journal of biological chemistry.
[12] P. Watkins,et al. Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol , 1992, Clinical pharmacology and therapeutics.
[13] P. Wedlund,et al. Genetic Aspects of Drug Disposition and Therapeutics , 1992, Journal of clinical pharmacology.